Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT06058039

PHASE3

Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

Sponsor: Neumora Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).

Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

332

Start Date

2023-12-21

Completion Date

2026-06

Last Updated

2026-04-08

Healthy Volunteers

Conditions

Major Depressive Disorder

Interventions

DRUG

NMRA-335140

Participants will receive NMRA-335140 at a dose of 80 mg QD, orally

DRUG

Placebo

Placebo will be administered orally

Key Inclusion Criteria: * Have a primary Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revised (DSM-5-TR) diagnosis of MDD without psychotic features confirmed by Structured Clinical Interview for DSM 5 Disorders, Clinical Trials Version (SCID 5 CT) at screening (this may be a first or recurrent episode). * Participant's current major depressive episode must be confirmed by independent assessment. * The symptoms of the current MDD episode have been present for more than 4 weeks prior to the Screening Visit, but no longer than 12 months prior to the Screening Visit. * Have a MADRS total score of 25 or higher at Screening and Baseline. * A change in MADRS total score between Screening and Baseline of ≤20%. Key Exclusion Criteria: * Have failed 2 or more courses of antidepressant treatment at sufficient doses for at least 6 to 8 weeks for the current MDD episode. * Currently or in the past year have been diagnosed with a personality disorder per the DSM-5-TR or in the past 3 years have been diagnosed with any of the following DSM-5-TR disorders: anorexia nervosa, bulimia nervosa, or binge eating disorder. Participants with comorbid generalized anxiety disorder, social anxiety disorder, simple phobias, or panic disorder for whom MDD is considered the primary diagnosis are not excluded. * Have a lifetime diagnosis of bipolar 1 or 2, schizophrenia, schizoaffective, schizophreniform, obsessive compulsive disorder, or post-traumatic stress disorder (PTSD). * Have moderate to severe substance or alcohol use disorder, per DSM-5-TR criteria, within the 12 months prior to screening (excluding nicotine). * Are actively suicidal (eg, any suicide attempts within the past 12 months) or are at serious suicidal risk as indicated by any current suicidal intent, including a plan, as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) (score of "YES" on suicidal ideations Item 4 or 5 within 3 months prior to Visit 1 \[Screening\]) and/or based on clinical evaluation by the Investigator; or are homicidal, in the opinion of the Investigator. Participants who are currently hospitalized for MDD symptoms or suicidality are not allowed into the study. If there is a recent history (within 3 months of screening) of hospitalization due to MDD symptoms, the participant should be discussed with the Medical Monitor for eligibility.

Locations (71)

Neumora Investigator Site

Cerritos, California, United States

Neumora Investigator Site

Irvine, California, United States

Neumora Investigator Site

Long Beach, California, United States

Neumora Investigator Site

San Diego, California, United States

Neumora Investigator Site

San Francisco, California, United States

Neumora Investigator Site

New Haven, Connecticut, United States

Neumora Investigator Site

Brandon, Florida, United States

Neumora Investigator Site

Hialeah, Florida, United States

Neumora Investigator Site

Hialeah, Florida, United States

Neumora Investigator Site

Jacksonville, Florida, United States

Neumora Investigator Site

Miami, Florida, United States

Neumora Investigator Site

Miami, Florida, United States

Neumora Investigator site

Miami, Florida, United States

Neumora Investigator Site

Miami Beach, Florida, United States

Neumora Investigator site

Miami Springs, Florida, United States

Neumora Investigator Site

Palm Bay, Florida, United States

Neumora Investigator Site

Pembroke Pines, Florida, United States

Neumora Investigator Site

Pompano Beach, Florida, United States

Neumora Investigator Site

Saint Augustine, Florida, United States

Neumora Investigator Site

Atlanta, Georgia, United States

Neumora Investigator Site

Decatur, Georgia, United States

Neumora Investigator Site

Savannah, Georgia, United States

Neumora Investigator Site

Springfield, Massachusetts, United States

Neumora Investigator Site

St Louis, Missouri, United States

Neumora Investigator Site

Omaha, Nebraska, United States

Neumora Investigator Site

Berlin, New Jersey, United States

Neumora Investigator Site

New York, New York, United States

Neumora Investigator Site

New York, New York, United States

Neumora Investigator Site

Staten Island, New York, United States

Neumora Investigator Site

Charlotte, North Carolina, United States

Neumora Investigator Site

Austin, Texas, United States

Neumora Investigator Site

DeSoto, Texas, United States

Neumora Investigator Site

Fort Worth, Texas, United States

Neumora Investigator Site

Plano, Texas, United States

Neumora Investigator Site

Cherven Bryag, Pleven, Bulgaria

Neumora Investigator Site

Sofia, Sofia-Grad, Bulgaria

Neumora Investigator Site

Sofia, Sofia-Grad, Bulgaria

Neumora Investigator Site

Sofia, Sofia-Grad, Bulgaria

Neumora Investigator Site

Kardzhali, Bulgaria

Neumora Investigator Site

Pleven, Bulgaria

Neumora Investigator Site

Targovishte, Bulgaria

Neumora Investigator Site #1

Varna, Bulgaria

Neumora Investigator Site

Varna, Bulgaria

Neumora Investigator Site

Pilsen, Plzen, Czechia

Neumora Investigator Site

Prague, Prague, Czechia

Neumora Investigator Site #1

Kladno, South Bohemian, Czechia

Neumora Investigator Site

Kladno, Czechia

Neumora Investigator Site

Prague, Czechia

Neumora Investigator Site

Helsinki, Etelä-Suomen Lääni, Finland

Neumora Investigator Site

Turku, Etelä-Suomen Lääni, Finland

Neumora Investigator Site

Oulu, Oulun Lääni, Finland

Neumora Investigator Site

Clermont-Ferrand, Auvergne-Rhône-Alpes, France

Neumora Investigator Site

Douai, Hauts-de-France, France

Neumora Investigator Site

Montpellier, Hérault, France

Neumora Investigator Site

Angers, Maine-et-Loire, France

Neumora Investigator Site

La Roche-sur-Yon, Vendée, France

Neumora Investigator Site

Poitiers, Vienne, France

Neumora Investigator Site #1

Berlin, Germany

Neumora Investigator Site

Berlin, Germany

Neumora Investigator Site

Berlin, Germany

Neumora Investigator Site

Berlin, Germany

Neumora Investigator Site

Hamburg, Germany

Neumora Investigator Site

Suchy Las, Greater Poland Voivodeship, Poland

Neumora Investigator Site

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Neumora Investigator Site

Wroclaw, Lower Silesian Voivodeship, Poland

Neumora Investigator Site

Lublin, Lublin Voivodeship, Poland

Neumora Investigator Site

Lublin, Lublin Voivodeship, Poland

Neumora Investigator Site

Bialystok, Podlaskie Voivodeship, Poland

Neumora Investigator Site

Gdansk, Pomeranian Voivodeship, Poland

Neumora Investigator Site

Lund, Skåne County, Sweden

Neumora Investigator Site

Stockholm, Stockholm County, Sweden

Clinical Research Directory

Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (71)